Findings demonstrate the potential of T2-weighted MRI in dual imaging and radiotherapy systems that aim to image and treat tumors simultaneously.
Browsing: lung cancer
Lung cancer risk assessment could be improved over existing guidelines by a four-protein biomarker blood test.
A team of researchers have developed the first comprehensive atlas of lung tumor cells.
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.
A preliminary report has revealed that a blood test could be used as a tool to detect early-stage lung cancer in patients.
Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer
Discover the case of nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer in this article from the impactful journal Immunotherapy.
Researchers have devised a method that allows them to personalize the lung cancer screening decision for every patient; the tool is termed Lung Decision Precision.
It can be a minefield to know which talks to look out for at ASCO! To help you navigate the largest conference in oncology, we have selected key talks for you to attend at ASCO18.
In this patient perspective find out T.J.’s viewpoint on the potentially practice-changing lung cancer findings presented at the AACR 2018.